049). Within the total IBD cohort, diarrhoea sub-score correlated with symptoms (r = 0.75, p = <0.001) and CLS (r = 0.43, p = 0.005) but abdominal pain as a symptom did not correlate to either (p > 0.05). On linear regression correcting for medication use, each increase of one diarrheal motion per day correlated with an increase in CLS of 2.14. (B coefficient = 2.14, selleck chemicals llc p = 0.005). Similarly a 1 point increase of CLS correlated to a 0.09 increase of diarrheal motions/day (B coefficient = 0.089, p = 0.004). Conclusion: Increased permeability may be responsible for ongoing symptoms

in patients who have achieved mucosal healing in both CD and UC. Increased permeability in symptomatic patients was best explained by diarrhea as a symptom. Reversal of impaired mucosal permeability may be a potential target

of treatment in these patients and should be evaluated in further studies. C KIELY,1 K SUBRAMANIAM,1 P PAVLI1 1Gastroenterology and Hepatology Unit, The Canberra Hospital, Garran, ACT, Australia Background: Biological therapy, particularly the anti-tumor necrosis factor antibodies, infliximab and adalimumab, are used for the maintenance of remission for patients selleck inhibitor with inflammatory bowel diseases (IBD; Crohn’s disease (CD) and ulcerative colitis (UC)). International guidelines recommend maintaining these agents throughout pregnancy and in the immediate post partum period1,2. Aim and Methods: To analyse maternal and Ureohydrolase fetal outcomes of pregnant patients with IBD treated with anti-TNF agents. Data for patients treated in a tertiary hospital was recorded prospectively and analyzed. Results: Nineteen pregnancies were recorded in 16 patients receiving anti-TNF therapy for IBD between 2007–2014 (Table 1). One patient with acute severe UC requiring colectomy during pregnancy had a stillbirth after attempted salvage therapy using adalimumab. Another patient admitted to

hospital during the third trimester with acute severe UC was treated successfully with infliximab rescue therapy. All other patients were in remission prior to pregnancy. One patient is currently pregnant and receiving anti-TNF therapy. Conclusion: Anti-TNF therapy can be used safely in pregnancy. Table 1   Crohn’s Disease (n = 14) Ulcerative Colitis (n = 5) All IBD (n = 19) Mean age at delivery (years) 34.3 32.6 33.8 Perianal disease 8 (57%) N/A 8 Concomitant medications azathioprine 3 (21%) 2 (40%) 5 (26%) prednisolone 5 (36%) 3 (60%) 8 (42%) Flare 3 (21%) 2 (40%) 5 (26%) Anti-TNF use adalimumab 8 (57%) 1 (20%) 9 (47%) infliximab 6 (43%) 4 (80%) 10 (53%) Continued use 3 (21%) 0 3 (16%) Cessation in 1st trimester 1 (7%) 0 1 (5%) Cessation in 3rd trimester 10 (71%) 4 (80%) 14 (74%) Commencement in 3rd trimester 0 1 (20%) 1 (5%) Gestational diabetes 2 (14%) 1 (20%) 3 (16%) Preterm delivery (<37 weeks) 1 (7%) 1 (20%) 2 (11%) Low birth weight (<3200 g) 7 (50%) 2 (40%) 9 (47%) Caesarian section 10 (71%) 2 (40%) 12 (63%) Congenital defects 0 0 0 1 Janneke van der Woude, C.